prgn-3006 in the treatment of aml and mds
Published 2 years ago • 59 plays • Length 1:20Download video MP4
Download video MP3
Similar videos
-
1:55
phase i/ib safety study of prgn-3006 ultracar-t in patients with r/r cd33-positive aml & hr-mds
-
2:49
the role of the immune system in the pathophysiology of mds
-
1:27
incorporating new technologies into the real-life classification of aml to guide treatment decisions
-
2:43
diagnostic tools for aml
-
1:41
using cytogenetics to improve the diagnosis and prognosis of mds & to predict response to treatment
-
1:57
gtb-3550 trike for the treatment of mds & aml
-
3:14
determining the optimal frontline treatment of aml
-
15:02
hematology myelodysplastic syndrome mds
-
0:46
prolonging survival in patients with aml ineligible for intensive chemotherapy
-
2:11
the current role of immuno-oncology in aml and future outlooks
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
2:48
validation of iwg 2023 criteria for response to treatment with hma in hr-mds
-
1:52
improving the use of mrd for the prognosis and treatment of all
-
2:03
preliminary results of a phase ii study of fedratinib in patients with mds/mpn and cnl
-
1:04
mp0533, a cd3-engaging darpin, in r/r aml or mds/aml: preliminary results of a phase i/iia trial
-
2:04
state-of-the-art treatment for hr-mds
-
1:12
the safety and efficacy of mb-106 for the treatment of waldenström’s macroglobulinemia
-
1:36
the importance of mrd as a prognostic tool in multiple myeloma
-
1:41
an overview of the mds diagnosis pathway